Frazier Life Sciences Acquisition II, the second blank check company formed by Frazier targeting the biotechnology sector, has filed with the SEC to raise up to $75 million in an initial public offering. The SPAC plans to offer 7.5 million shares at $10 each without warrants or rights, with proceeds intended to support a biotech company developing new therapies.

Company Background

Frazier Life Sciences Acquisition II is led by CEO and Director Albert Cha, a Managing Partner at Frazier Life Sciences, which originated as the life sciences strategy of Frazier Healthcare Partners.

The SPAC plans to focus specifically on the biotechnology sector, seeking a company capable of developing important new therapies for patients while creating value for shareholders. The new vehicle represents Frazier’s second SPAC focused on the life sciences industry.

Frazier’s previous SPAC, Frazier Life Sciences Acquisition, completed its business combination with cardiometabolic disease biotechnology company NewAmsterdam Pharma in 2022. NewAmsterdam Pharma trades on Nasdaq under the symbol NAMS.

IPO Details

Frazier Life Sciences Acquisition II plans to raise $75 million by offering 7.5 million shares at $10 per share. Unlike many SPAC offerings, the transaction does not contain warrants or rights.

The Palo Alto, California-based company was founded in 2026 and plans to list on the Nasdaq under the symbol FLSC. Jefferies is serving as the sole bookrunner on the offering.

Market Context & Opportunities

The SPAC is entering the public markets with a narrowly defined mandate focused on biotechnology. Its connection to Frazier Life Sciences provides an investment platform centered on life sciences, while its previous SPAC transaction with NewAmsterdam Pharma establishes an earlier example of Frazier using the blank-check structure to pursue a biotech combination.

The planned focus on companies developing new therapies also places the SPAC within a sector where clinical-stage businesses can require significant capital to advance drug development programs.

Risks & Challenges

A biotechnology-focused SPAC faces the uncertainty associated with identifying and completing a suitable business combination. The company has not disclosed a specific target, meaning the eventual investment opportunity will depend on the business it selects and the terms of any future transaction.

Biotech companies also typically face development and commercialization risks, although the filing information provided does not identify a specific target or clinical program for Frazier Life Sciences Acquisition II.

Closing Paragraph

Frazier Life Sciences Acquisition II is positioning its $75 million IPO as a vehicle dedicated to biotechnology, with no warrants or rights attached to its offering. Led by Frazier Life Sciences Managing Partner Albert Cha, the SPAC builds on the firm’s previous combination with NewAmsterdam Pharma while beginning a new search for a biotech company capable of advancing novel therapies.